Nan Fung Life Sciences antes up $32M to fuel a neuro play as the Hong Kong conglomerate burns through $1.5B mandate
Having relied heavily on its Pivotal bioVentures Partners arm to make direct investments in biotech, Nan Fung Life Sciences is taking an increasingly prominent seat at the table, putting up $32 million as the sole investor in a neuroscience startup’s launch round.
With the Series A Engrail Therapeutics is also taking the covers off its business model, which involves finding, buying and then developing drugs for brain disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.